SHUKRA PHARMACEUTICALS LIMITED

(Formerly known as Relish Pharmaceutical Limited)

R.O.: 3rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev, Ahmedabad Ahmedabad GJ 380054 | Phone: (079)66522247, Fax: 079-27498515 | Email: info@relishpharma.com , Website: www.relishpharma.com | CIN: L24231GJ1993PLC019079

14th February, 2017

To, The General Manager-Listing Corporate Relationship Department The BSE Limited, Ground Floor, P.J. Towers, Dalal Street, Mumbai

Scrip Code: 524632

Dear Sir,

Sub.: Outcome of Board Meeting

With reference to above subject and in compliance with the Listing Agreement, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 14th February, 2017 at 03.30 pm and concluded at 6.00 p.m.:-

1) Approval of Unaudited Financial Results for the quarter ended on 31st December, 2016.

You are requested to kindly take the same on record.

Thanking You

Yours faithfully,

For Shukra Pharmaceuticals Limited (Formerly known as Relish Pharmaceuticals Limited)

Dakshesh R. Shah

Director DIN: 00561666

SHUKRA PHARMACEUTICALS LTD

Regd. Off.: 3rd Floor, Dev House, Judges Bunglow Road, Bodak Dev, Ahmedabad - 54 CIN: L24231GJ1993PLC019079

	Particulars	3 Months Ended	3 Months Ended	3 Months Ended	9 Months Ended	9 Months Ended	Year to date	
		(31-12-2016)	(30-09-2016)	(31-12-2015)	(31-12-2016)	(31-12-2015)	figures for	
-							current period	
							ended	
							(31/03/2016)	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Income from operations			1-1	1-1-1-1-1			
	(a) Net sales/income from operations	132.94	184.93	36.58	317.87	158.62	482.40	
-	(Net of excise duty)			5.8 (SU)	distantion of			
-	(b) Other operating income	0.00	0.00	0.00	0.00	100.00		
	Total income from operations (net)	132.94	184.93	36.58	317.87	258.62	482.40	
2	Expenses					and the second se		
	(a) Cost of materials consumed	26.84	43.31	20.71	70.15	65.63	77.30	
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00	
	(c) Changes in inventories of finished goods,	-0.45	3.62	-31.53	3.17	1.58	91.20	
-	work-in-progress and stock-in-trade						Contraction of the second s	
	(d) Employee benefits expense	35.09	49.51	27.29	84.60	88.99	115.80	
-	(e) Depreciation and amortisation expense	9.25	24.35	15.00	33.60	45.00	44.80	
-	(f) Other expenses (Any item exceeding	48.22	30.16	11.88	78.38	45.49	79.40	
	10% of the total expenses relating to							
-	continuing operations to be shown							
	separately)							
-	Total expenses	118.95	150.95	43.35	269.90	246.69	408 50	
3	Profit / (Loss) from operations before other	13.99	33.98	(6.77)	47.97	11.93	73.90	
	income, finance costs and exceptional			1.5				
	items (1-2)							
4	Other income	0.96	2.43	0.63	3.39	1.94	6.8	
	Profit / (Loss) from ordinary activities	14.95	36.41	(6.14)	51.36	13.87	80.70	
-	before finance costs and exceptional items							
-	(3 + 4)							
6	Finance costs	0.00	0.00	0.00	0.00	0.00	0.10	
7	Non-the-	14.95	36.41	(6.14)	51.36	13.87	80.60	
-	finance costs but before exceptional items	14.00	00.41	101147	01.00	10.07	00.00	
-	(5+6)							
12	Exceptional items	0.00	0.00	0.00	0.00	0.00	-40 60	
9		14.95	36.41	(6.14)	51.36	13.87	40.00	
	before tax	14:55	00.41	(0.14)	51.50	13.07	40.00	
	(7 + 8)							
10	Tax expense - Provision for taxation	4.50	11.50	0.00	16.00	0.00	23 10	
	Net Profit / (Loss) from ordinary activities	10.45	24.91	(6.14)	35.36	13.87	16.90	
**	after tax (9 + 10)	10,45	61.01	10.147	00.00	10.01	10.00	
12	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00	
		0.00	0.00	0.00	0.00	0.00	0.00	
13	Net Profit / (Loss) for the period (11 + 12)	10.45	24.91	(6.14)	35.36	13.87	16.90	
	Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00	
_	Minority interest *	0.00	0.00	0.00	0.00	0.00	0.00	
	Net Profit / (Loss) after taxes, minority	10.45	24.91	(6.14)	35.36	13.87	16.90	
10	interest and share of profit / (loss) of	10.45	24.31	(0.14)	33.30	15.07	10.30	
-	associates (13 + 14 + 15) *							
17	Paid-up equity share capital	156.57	156.57	156.57	156.57	156.57	156.57	
	(Face Value of the Share shall be indicated)	100.07	100.07	1.00-07	130.57	100,07	100.57	
18	Reserve excluding Revaluation Reserves as	0.00	0.00	0.00	0.00	0,00	0.00	
	per balance sheet of previous accounting year						0.00	
9.1	Earnings per share (before extraordinary							
	items)							
-	(of Rs 10/- each) (not annualised):							
	(a) Basic	0.07	0.16	(0.04)	0.23	0.09	0.11	
	(b) Diluted	0.07	0.16	(0.04)	0.23	0.09	0.11	
.9.ii	Earnings per share (after extraordinary							
	items)							
	(of Rs 10/- each) (not annualised):							
	(a) Basic	0.07	0.16	-0.04	0.23	0.09	0.11	
-	(b) Diluted	0.07	0.16	-0.04	0.23	0.09	0.11	

Notes: 1. The above results were reviewed by Audit Committee and taken on record by the Board of

Directors at its meeting held on 14th February 2017

2. The Company has only single Reportable Business Segment in terms of requirements of Accounting Standard 17.

3. Previous quarter's figures have been re-grouped / re-arranged wherever necessary.

Place : Ahmedabad Date : 14/02/2017

PARTI

For, Shukra Pharmaceauticals Limited For Shukra Pharmaceuticals Limited Director/Authorised Signatory

		SHUKRA	PHARMACEUTICA	LS LTD			
	Regd. Off.: 3rd Floor, Dev House	, Judges Bunglow I	Road, Bodak Dev,	Ahmedabad - 5	4 CIN: L24231G	J1993PLC019079	
PAR	RT II						
			Quarter Ended 3				,
	Particulars	3 Months Ended	3 Months Ended	3 Months Ende	9 Months Ended	9 Months Ended	Year to date
		(31-12-2016)	(30-09-2016)	(31-12-2015)	(31-12-2016)	(31-12-2015)	figures for
							current period
							ended
							(31/03/2016)
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	- Number of shares	769770	769770	769770	769770	769770	769770
	- Percentage of shareholding	49.17%	49.17%	49.17%	49.17%	49.17%	49.17%
2	Promoters and Promoter Group Shareholdir	ng **					
	a) Pledged/Encumbered		1				
	- Number of shares	0.00	0.00	0.00	0.00	0.00	0.00
	- Percentage of shares (as a % of the total	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	shareholding of promoter and promoter						
	group)						
	- Percentage of shares (as a % of the total	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	share capital of the company)						
	b) Non-encumbered						
	- Number of shares	795905	795905	795905	795905	795905	795905
	- Percentage of shares (as a % of the total	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	shareholding of the Promoter and						
	Promoter group)						
	- Percentage of shares (as a % of the total	50.83%	50.83%	50.83%	50.83%	50.83%	50.83%
	share capital of the company)						

	Particulars	3 months ended 31/12/2016
В	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	
	Received during the quarter	
	Disposed of during the quarter	
	Remaining unresolved at the end of the quarter	

Place : Ahmedabad Date : 14/02/2017 For, Shukra Pharmaceauticals Limited For Shukra Pharmaceuticals Limited

Director/Authorised Signatery DIN : 07032481

SHUKRA PHARMACEUTICALS LIMITED

STATEMENT OF ASSETS AND LIABILITIES	STANDA	LONE
	As at current period ended 31-12-2016	As at current year end 31-3-2016
	(Unaudited)	(Audited)
A EQUITY AND LIABILITIES		
1 SHAREHOLDERS FUNDS		
(a) Share Capital	156.57	156.57
(b) Reserves and surplus	1271.19	1250.78
(c)Money received against share warrant		
SHAREHOLDERS FUNDS	1427.76	1407.35
2 SHARE APPLICATION MONEY PENDING ALLOTMENT		
3 NON - CUURENT LIABLITIES		
(a) Long-term borrowing	0	C
(b) Defered tax liabilities (net)	244.14	244.14
(c)Other long-term liabilities		C
(d) long-term provisions		C
NON - CURENT LIABLITIES	244.1	244.1
4 CURRENT LIABILITIES		
(a) Short-term borrowing	3.6	3.6
(b) Trade payables	22.87	25.55
(c) Other current laibilities	0	0
(d) Short- term provision	17.11	0
CURRENT LIABILITIES	43.58	29.15
TOTAL EQUITY AND LIABILITIES	1715.48	1681
BASSETS		
1 NON - CURRENT ASSETS		
(a) Fixed assets	1130.91	1135.6
(b) Non- current investments	4.15	4.15
(c) Deferred tax assets (net)		C
(d) long-term loans and advances		C
(e) Other non-current assets	8.27	9.27
NON - CURRENT ASSETS	1143.33	1149.02
2 CURRENT ASSETS		
(a) Currents investments	0	C
(b) Inventories	40.22	, i i i i i i i i i i i i i i i i i i i
(c) Trade receivables	109.48	
(d) Cash and cash equivalents	119.54	
(e) Short-term loans and advances	262.39	
(f) Other current asets	40.52	
CURRENT ASSETS	the second	
TOTAL ASSETS		

For Shukra Pharmaceuticals Limited
ater
Director/Authorised Signatory

THE T